Kristin Strogus, PA
Medical · Philadelphia, PANPI 1669706974
Payments from drug & device makers
Across 51 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$231
- Johnson & Johnson$229
- Merck$133
- Gilead$56
- Stemline Therapeutics Inc.$53
- Eisai Inc.$49
- plus $458 from 18 others
What the payments were for
- Food & beverage$1,209100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 10 | $231 |
| Johnson & Johnson | 9 | $229 |
| Merck | 5 | $133 |
| Gilead | 2 | $56 |
| Stemline Therapeutics Inc. | 2 | $53 |
| Eisai Inc. | 2 | $49 |
| Exelixis Inc. | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $27 |
| Sobi, Inc | 1 | $27 |
| Amgen | 1 | $26 |
| Incyte Corporation | 1 | $26 |
| Seagen Inc. | 1 | $23 |
| Pfizer | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| AbbVie | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Genmab U.S., Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $16 |
| AstraZeneca | 1 | $13 |
How this compares
$1,209 in reported general payments places this provider in the 70th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 33 | $454 |
| Finasteride | 25 | $169 |
| Neomycin Sulfate | 11 | $53 |
| Metronidazole | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Other medical in Philadelphia
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Sarah SmithPhiladelphia$65K
- Victoria WongPhiladelphia$51K
- Parth PatelPhiladelphia$46K
- Zachary LutzPhiladelphia$30K
- Hawah MusaPhiladelphia$13K
- Carl BlackPhiladelphia$13K
- Ashley BarratPhiladelphia$12K
- Jacqueline KernaghanSpringfield$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.